Progression-free survival of NLPHL patients from the HD16 study according to the cut-off for iPET positivity. PFS of patients with NLPHL from the HD16 study with either a positive or negative iPET result: if a DS <3 is considered as an iPET-negative result (A) and if a DS <4 is considered as an iPET-negative result (B). iPET, PET-2.